Company Name Xoft
Mailing Address 345 Potrero Avenue Sunnyvale, CA 94085
Company Description Xoft is an innovative technological leader revolutionizing the practice of radiation oncology through electronic brachytherapy with proprietary miniaturized x-ray tube technology. Xoft is dedicated to providing the most intelligent, efficacious, and cost-effective therapy for patients, health-care providers, and payers alike.
M&A Terms iCAD plans to acquire 100% of the outstanding stock of Xoft in exchange for approximately 8.47 million shares of iCAD common stock and approximately $1.0 million in cash to certain shareholders, for a total consideration at closing of approximately $13.1 million, based on the average of the closing sale price of the Company’s common stock over the thirty trading days immediately preceding the closing date. The threshold for earn-out consideration begins at $50 million of cumulative revenue of Xoft products over the three year period immediately following the closing. The “targeted” earn-out consideration of $20 million will occur at $76 million of cumulative revenue of Xoft products and the maximum earn-out consideration of $40 million would be achieved at $104 million of cumulative Xoft product revenue over the three year period.